ATC Group: H01AC06 Tesamorelin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H01AC06 in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H01 Pituitary and hypothalamic hormones and analogues
3 H01A Anterior pituitary lobe hormones and analogues
4 H01AC Somatropin and somatropin agonists
5 H01AC06 Tesamorelin

Active ingredients in H01AC06

Active Ingredient

Tesamorelin is indicated for the treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients with lipodystrophy. In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF, and subsequently increases IGF-1 and IGFBP-3 levels.

Related product monographs

Document Type Information Source  
 EGRIFTA Powder for solution fot injection MPI, CA: SPM Health Products and Food Branch (CA)
 EGRIFTA SV Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicines in this ATC group

United States (US)

Canada (CA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.